Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Cited by (1,000)

Items 901–1,000 of 1,000

1. Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma
   Jens Bedke, Stephan Kruck, Georgios Gakis, Arnulf Stenzl, Peter Jürgen Goebell · 2015 · Human Vaccines & Immunotherapeutics
2. Cytotoxic Activity of Dendritic Cells as a Possible Mechanism of Negative Regulation of T Lymphocytes in Pulmonary Tuberculosis
   Ludmila V. Sakhno, Marina Aleksandrovna Tikhonova, Тыринова Тамара Викторовна, O. Yu. Leplina, Е. Ya. Shevela, Sergey D. Nikonov, O. A. Zhdanov, Alexander A. Ostanin, Elena Removna Chernykh · 2012 · Clinical and Developmental Immunology
3. The Effect of Low-Dose Chemotherapy on the Tumor Microenvironment and its Antitumor Activity Combined with Anti-PD-1 Antibody
   Fang-Yu Lin, Hao Chen, Tao Jiang, Jianwei Zheng, Qin Liu, Baoyu Yang, Xinli Wang, Xiaoyan Lin · 2022 · Immunotherapy
4. PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade
   Chiara Donini, Federica Galvagno, Ramona Rotolo, Annamaria Massa, Alessandra Merlini, Giorgio V. Scagliotti, Silvia Novello, Paolo Bironzo, Valeria Leuci, Dario Sangiolo · 2023 · British Journal of Cancer
5. Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach
   Maciej Grzywnowicz, Krzysztof Giannopoulos · 2012 · Acta Haematologica Polonica
6. Peritoneal Immune System in Patients with Advance Epithelial Ovarian Cancer
   Iwona Wertel, Aldona Nowicka, Ewelina Rogala, Jan Kotarski · 2011 · International Reviews of Immunology
7. The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response
   Pavlína Zatloukalová, Mariana Pjechová, S Babcanová, Theodore Robert Hupp, Bořivoj Vojtěšek · 2016 · Klinicka onkologie
8. The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial
   Andrea Botticelli, Silvia Mezi, Giulia Pomati, Paolo Sciattella, Bruna Cerbelli, Michela Roberto, Giulia Mammone, Alessio Cirillo, Alessandra Cassano, Carmela Di Dio et al. · 2020 · Vaccines
9. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma
   Marta Maestri, Maria Pallozzi, Francesco Santopaolo, Lucia Cerrito, Maurizio Pompili, Antonio Gasbarrini, Francesca Romana Ponziani · 2022 · Expert Opinion on Investigational Drugs
10. Immunotherapy for Prostate Cancer: An Emerging Treatment Modality
    Charles G. Drake · 2010 · Urologic Clinics of North America
11. Employing the immunological synapse in AML: Development of leukemic dendritic cells for active specific immunization
    Ilse Houtenbos, Theresia M. Westers, Gert Jan Ossenkoppele, Arjan A. van de Loosdrecht · 2005 · Immunobiology
12. Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function
    Seigo Terawaki, Yoshimasa Tanaka, Tomokazu Nagakura, T. Hayashi, S. Shibayama, K. Muroi, Taku Okazaki, Bunzo Mikami, David N. Garboczi, T Honjo et al. · 2007 · International Immunology
13. Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines
    Grégoire Wieërs, Nathalie Demotte, Danièle Godelaine, Pierre van der Bruggen · 2011 · Cancers
14. Investigation on the effects of soluble programmed death-1 (sPD-1) enhancing anti-tumor immune response
    Ye Yuan, He Yufei, Wang Xiaohong, Hui Zhang, Dong Li, Feng Zuohua, Zhang Guimei · 2004 · Current Medical Science
15. Insights into the Mechanisms of Immune‐Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment
    Yuanyuan Zhang, Zhihua Liu · 2025 · Advanced Science
16. HIV-1 induction of tolerogenic dendritic cells is mediated by cellular interaction with suppressive T cells
    Cecilia Svanberg, Sofia N. Nyström, Melissa Govender, Pradyot Bhattacharya, Karlhans F Che, Rada Ellegård, Esaki Muthu Shankar, Marie Larsson · 2022 · Frontiers in Immunology
17. Unique characteristics of the tumor immune microenvironment in young patients with metastatic colorectal cancer
    Brian D. Griffith, Jenny Lazarus, Jake J. McGue, Santhoshi Krishnan, Michael Ian D'Angelica, Jinru Shia, Irina Y. Dobrosotskaya, Jiaqi Shi, Jacob Edwards, Arvind U.K. Rao et al. · 2023 · Frontiers in Immunology
18. Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases
    Курилин Василий Васильевич, Alina Alshevskaya, Sergey Vitalievich Sennikov · 2024 · Biomedicines
19. PHD2 Constrains Antitumor CD8+ T-cell Activity
    Charlotte Bisilliat Donnet, Valérie Acolty, Abdulkader Azouz, Anaëlle Taquin, Coralie Henin, Sarah Trusso Cafarello, Sébastien Denanglaire, Massimiliano Mazzone, Guillaume Oldenhove, Oberdan Léo et al. · 2023 · Cancer Immunology Research
20. Inhibitory RNA Molecules in Immunotherapy for Cancer
    Chih-Ping Mao, T.‐C. Wu · 2010 · Methods in molecular biology
21. CD28 ligation increases macrophage suppression of T-cell proliferation
    Daniel Silberman, Amanda Bucknum, Thomas M. Bartlett, Gabriella M. Composto, Megan Kozlowski, Amanda Walker, Amy Werda, Jackelyn Cua, Arlene H. Sharpe, John E. Somerville et al. · 2012 · Cellular and Molecular Immunology
22. Ovarian Cancer-derived Glycodelin Impairs In Vitro Dendritic Cell Maturation
    Christoph Scholz, Elisabeth Rampf, Bettina Tóth, Regina Brunnhuber, Tobias M. Weissenbacher, Klaus Friese, Udo Jeschke · 2009 · Journal of Immunotherapy
23. Inhibitors of B7–CD28 Costimulation in Urologic Malignancies
    Robert Houston Thompson, Eugene D. Kwon, James Patrick Allison · 2008 · Immunotherapy
24. Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy
    Kai Shi, Matthew T. Haynes, Leaf Huang · 2017 · Frontiers of Chemical Science and Engineering
25. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
    Hannah Yejin Kim, Parth J. Upadhyay, Alia Fahmy, Xiaoman Liu, Janna K. Duong, Alan V. Boddy · 2019 · Clinical Pharmacokinetics
26. Stimulatory and Inhibitory Co-signals in Autoimmunity
    Taku Okazaki, Il‐mi Okazaki · 2019 · Advances in experimental medicine and biology
27. Costimulation in Lymphomas and Cancers
    Manzoor Ahmad Mir · 2015 · Elsevier eBooks
28. Cytokine treatment of macrophage suppression of T cell activation
    Daniel Silberman, Amanda Bucknum, Megan Kozlowski, Robin Matlack, James Edward Riggs · 2009 · Immunobiology
29. Using antibodies in tumour immunotherapy
    Birgit C. Schultes, Christopher F. Nicodemus · 2004 · Expert Opinion on Biological Therapy
30. Immune checkpoint protein PD-L1 promotes transcription of angiogenic and oncogenic proteins IL-8, Bcl3, and STAT1 in ovarian cancer cells
    S Paddy Reddy, Rachel Sham, Khalani Smith, Bijaya Gaire, Aleš Vančura, Ivana Vancurova · 2025 · Journal of Biological Chemistry
31. Erythrocyte–anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial
    Xiaoqian Nie, Yuehua Liu, Xingyun Yao, Qi Zhang, Yanjie Huang, Kurban Mattursun, Yuxiong Feng, Ting Liang, Liu Yang, Xiaofei Gao · 2026 · Nature Cancer
32. Self-reactive T cells: suppressing the suppressors
    Jürgen Christian Becker, Per thor Straten, Mads Hald Andersen · 2013 · Cancer Immunology Immunotherapy
33. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
    Jens Bedke, Arnulf Stenzl · 2013 · Expert Review of Anticancer Therapy
34. What does radiomics do in PD‐L1 blockade therapy of NSCLC patients?
    Ruichen Cui, Zhenyu Yang, Lunxu Liu · 2022 · Thoracic Cancer
35. Leprosy as a model to understand cancer immunosurveillance and T cell anergy
    Andrew J Park, Tina Rendini, Frank T. Martiniuk, William R. Levis · 2016 · Journal of Leukocyte Biology
36. Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild‑type disease during the early disease course
    Jung‐Min Lee, Dana‐Adriana Botesteanu, Yusuke Tomita, Akira Yuno, Min‐Jung Lee, Elise C. Kohn, Christina M. Annunziata, Ursula A. Matulonis, Lauren A. MacDonald, Jayakumar R. Nair et al. · 2019 · Oncology Letters
37. Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
    Sae Ohwada, Keisuke Ishigami, Noriyuki Akutsu, Hiroshi Nakase · 2022 · Biomedicines
38. The role of cytotoxic T cells in IgG4-related dacryoadenitis and sialadenitis, the so-called Mikulicz's disease
    Tetsuya Tabeya, Motohisa Yamamoto, Yasuyoshi Naishiro, Keisuke Ishigami, Yui Shimizu, Hidetaka Yajima, Chisako Suzuki, Nobuhiko Seki, Kenichi Takano, Tetsuo Himi et al. · 2014 · Modern Rheumatology
39. Immunothérapie dans le cancer bronchique non à petites cellules : inhibition de la voie PD1/PDL1
    Laurent Guilleminault, D. Carmier, Nathalie Heuzé‐Vourc'h, P. Diot, Éric Pichon · 2015 · Revue de Pneumologie Clinique
40. Therapeutic Vaccine for Lymphoma
    Seung‐Tae Lee, Sattva Swarup Neelapu, Larry W. Kwak · 2007 · Yonsei Medical Journal
41. Intratumoural administration of dendritic cells: hostile environment and help by gene therapy
    Eduardo Huarte, Iñigo Tirapu, Ainhoa Arina, María Vera, Carlos Alfaro, Oihana Murillo, Belén Palencia, Victoria Busto, Verónica Marín, Guillermo Daniel Mazzolini et al. · 2005 · Expert Opinion on Biological Therapy
42. Lipid Nanoparticles and PEG: Time Frame of Immune Checkpoint Blockade Can Be Controlled by Adjusting the Rate of Cellular Uptake of Nanoparticles
    Andrew S. Choi, Taylor J. Moon, Anubhuti Bhalotia, Aarthi Rajan, Laolu Ogunnaike, Diarmuid W. Hutchinson, Inga Hwang, Aaditya Gokhale, Justin N. Kim, Timothy Ma et al. · 2025 · Molecular Pharmaceutics
43. Combination of immune checkpoint inhibitors and anti-angiogenic agents: An emerging strategy for cancer therapy
    Yunyi Li, Lu Yang, Liu Zd · 2025 · Critical Reviews in Oncology/Hematology
44. Evaluation of 89 Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET
    Bhasker Radaram, Sarah E. Glazer, Ping Yang, Chia‐Wei Li, Mien‐Chie Hung, Seth T. Gammon, Mian M. Alauddin, David R Piwnica-Worms · 2023 · ACS Omega
45. Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment
    Chin‐Jui Wu, Ke‐Fan Pan, Ji‐Qing Chen, Tao Yu, Yu‐Cheng Liu, Bo-Rong Chen, Ching Hsiang Hsu, Mingyang Wang, Bor‐Ching Sheu, Michael Hsiao et al. · 2024 · Oncogene
46. Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics
    Peng Tan, Amrit S. Lota · 2008 · Expert Opinion on Pharmacotherapy
47. Cellular and molecular immunology of lung cancer: therapeutic implications
    Austin Huy Nguyen, Ilya G. Berim, Devendra K. Agrawal · 2014 · Expert Review of Clinical Immunology
48. Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors
    Chang Jiang, Xiuyu Cai, Hongxia Zhang, Xiaojun Xia, Bei Zhang, Liangping Xia · 2017 · Journal of Cancer
49. Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand in�vitro
    Zilong Hu, Yue Ma, Zhiyang Shang, Shidong Hu, Kai Liang, Wentao Liang, Xiaowei Xing, Yufeng Wang, Xiaohui Du · 2018 · Oncology Letters
50. Nivolumab in squamous cell carcinoma of the head and neck
    Pol M. Specenier · 2018 · Expert Review of Anticancer Therapy
51. Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
    Silvia Martin Lluesma, Michele Graciotti, Cheryl Lai-Lai Chiang, Lana Elias Kandalaft · 2018 · Vaccines
52. Immune Checkpoint Blockers and Ovarian Cancer.
    Chinmoy Kr. Bose · 2017 · PubMed Central
53. Extracellular Vesicles in Reprogramming of the Ewing Sarcoma Tumor Microenvironment
    Manideep Chowdary Pachva, Horton Lai, A-lin Jia, M. Rouleau, P. Sorensen · 2021 · Frontiers in Cell and Developmental Biology
54. Light-controlled elimination of PD-L1+ cells
    Judith Jing Wen Wong, Pål Kristian Selbo · 2021 · Journal of Photochemistry and Photobiology B Biology
55. The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies
    Malcolm Holterhus, Bianca Altvater, Sareetha Kailayangiri, Claudia Rössig · 2022 · Cancers
56. Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
    Taylor J. Brueseke, Krishnansu S. Tewari · 2013 · Clinical Pharmacology Advances and Applications
57. Advances in the systemic treatment of metastatic melanoma.
    Melinda Lynne Yushak, Harriet M. Kluger, Mario Sznol · 2013 · PubMed
58. Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent glutathione pathway
    Derek B. Oien, JEREMY R. CHIEN, Nikki Cheng · 2016 · Translational Cancer Research
59. Strategies of Antigen-Specific T-Cell–Based Immunotherapy for Cancer
    Suhu Liu, Mei Zhang, Wanggang Zhang · 2005 · Cancer Biotherapy and Radiopharmaceuticals
60. Fine-Tuned Expression of Programmed Death 1 Ligands in Mature Dendritic Cells Stimulated by CD40 Ligand Is Critical for the Induction of an Efficient Tumor Specific Immune Response
    Tao Gu, Yibei Zhu, Cheng Chen, Min Li, Yongjing Chen, Ge-Hua Yu, Yan Ge, Shi-Yong Zhou, Huan Zhou, Yong Huang et al. · 2008 · Cellular and Molecular Immunology
61. Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma
    Manohan Sinnadurai, Kerrie Leanne McDonald · 2017 · Journal of Neuro-Oncology
62. Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells
    Jong Shin, Siavash Raissi, Paul Phelan, Peter A. Bullock · 2022 · Protein Expression and Purification
63. Ovarian cancer stem cells: Critical roles in anti-tumor immunity
    Jing Ding, Yan Zhang, Yan Che · 2022 · Frontiers in Genetics
64. BIN1 in cancer: biomarker and therapeutic target
    Siyu Chen, Jinlong Cao, Kunpeng Li, Shun Wan, Yang Li · 2023 · Journal of Cancer Research and Clinical Oncology
65. Programmed Death 1 Receptor ChangesEx Vivoin HIV-Infected Adults following Initiation of Highly Active Antiretroviral Therapy
    Sergei V. Spitsin, Nancy B. Tustin, Eric Riedel, Richard Tustin, Jennifer B. Murray, Lauren M. Peck, Mohammad Khan, Joseph Quinn, Steven D. Douglas · 2012 · Clinical and Vaccine Immunology
66. PD-L1 expression in regional lymph nodes and predictable roles in anti-cancer immune responses
    Yoshihiro Komohara, Mamoru Harada, Koji Ohnishi, Keiichiro Kumamoto, Toshiyuki Nakayama · 2020 · Journal of the Japan Society of the Reticuloendothelial System
67. Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodes
    Eric Salgado, Yanguang Cao · 2020 · Mathematical Biosciences & Engineering
68. Alternate vehicles for diagnostic patch testing: an update.
    C Cyran, Howard Ira Maibach · 2008 · PubMed
69. Genetic modification of T cells for immunotherapy
    Carolina Berger, Michael Berger, Junli Feng, Stanley R. Riddell · 2007 · Expert Opinion on Biological Therapy
70. Immune Escape
    Theresa L. Whiteside, Michael R. Campoli, Soldano Ferrone · 2005 · Springer eBooks
71. Double-edged roles of IFNγ in tumor elimination and immune escape
    Yueyue Chen, Ningning Niu, Jing Xue · 2023 · Journal of Pancreatology
72. The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
    Nathan J. Dean, Paolo D. d’Arienzo, Hajir Ibraheim, Karla A. Lee, Anna Claire Olsson-Brown, David James Pinato, Nick Powell · 2024 · Best Practice & Research Clinical Gastroenterology
73. Citrullination in tumor immunity and therapy
    Michael Reginald Pitter, Weiping Zou · 2025 · Journal of Clinical Investigation
74. Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment
    Shirin Bonni, David N. Brindley, Michael Dean Chamberlain, Nima Daneshvar Baghbadorani, Andrew Freywald, Denise G. Hemmings, Sabine Hombach‐Klonisch, Thomas C. Klonisch, Afshin Raouf, Carrie Simone Shemanko et al. · 2024 · Cancers
75. Inflammatory and Innate Immune Cells in Cancer Microenvironment and Progression
    Patrick Brennecke, Paola Allavena, Ilaria Laface, Alberto Mantovani, Barbara Bottazzi · 2014 · Springer eBooks
76. Anti-PD-1-Targeted Therapies Focusing on Lymphatic Malignancies: Biological Rationale, Clinical Challenges and Opportunities
    Meirav Kedmi, Abraham Avigdor, Arnon Nagler · 2014 · Acta Haematologica
77. A new approach to produce IgG4-like bispecific antibodies
    Caizhi Zhao, Wei Zhang, Guihua Gong, Liping Xie, Ming‐Wei Wang, Youjia Hu · 2021 · Scientific Reports
78. Mechanisms of Altered Immune Response in Skin Melanoma.
    Radu-Florin Fruntealată, Matei Marius, Ianis Kevyn Ştefan Boboc, Smaranda Ioana Mitran, Marius Eugen Ciurea, George Alin Stoica · 2023 · PubMed Central
79. Combination of C-reactive Protein and Monocyte Count Is a Useful Prognostic Indicator for Patients With Colorectal Cancer
    Manabu Yamamoto, Hiroaki Saito, Kazushi Hara, Ken Sugezawa, Chihiro Uejima, Akimitsu Tanio, Yoichiro Tada, Kyoichi Kihara, Teruhisa Sakamoto, Soichiro Honjo et al. · 2019 · In Vivo
80. Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy
    Sina Abdkarimi, Saiedeh Razi Soofiyani, Goli Elham, Hossein Mashhadi Abdolahi, Elham Safarzadeh, Behzad Baradaran · 2020 · European Journal of Cancer Care
81. Programmed Cell Death Ligand 1 Is Enriched in Mammary Stem Cells and Promotes Mammary Development and Regeneration
    Ruirui Wang, Fujing Huang, Wei Wei, Yu Zhou, Zi Ye, Liya Yu, Junyuan Hu, Cheguo Cai · 2021 · Frontiers in Cell and Developmental Biology
82. Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?
    Bruno Quesnel · 2006 · Expert Review of Vaccines
83. Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model
    Benedict A. Capacio, Jayanth S. Shankara Narayanan, Diego A. Vicente, Yujia Liu, Jason P. LaPorte, Bryan F. Cox, David Jaroch, Steven C. Katz, Rebekah Ruth White · 2023 · Surgery
84. New expression of PD-L1 on activated CD4+ T cells opens up new opportunities for cell interactions and signaling
    Fabienne Mazerolles · 2024 · Human Immunology
85. TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer
    Mitchell Thomas McGinty, Audrey Marie Putelo, Sree H. Kolli, Tzu-Yu Feng, Madison R. Dietl, Cara N. Hatzinger, Simona Bajgai, Mika K. Poblete, Francesca N. Azar, Anwaruddin Mohammad et al. · 2025 · Cancer Immunology Research
86. RETRACTED ARTICLE: Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma
    Hamid Reza Safaei, Ayoob Rostamzadeh, Omid Rahmani, Mohsen Mohammadi, Omar Ghaderi, Hamid Yahaghi, Koroosh Ahmadi · 2015 · Tumor Biology · Retracted
87. A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice
    Fei Tang, Peng Zhang, Peiying Ye, Christopher A. Lazarski, Qi Wu, Ingrid L. Bergin, Timothy P. Bender, Michael N. Hall, Ya Cui, Liguo Zhang et al. · 2017 · eLife
88. The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
    Brigida Anna Maiorano, Alessandro Parisi, Evaristo Maiello, Davide Ciardiello · 2022 · Life
89. Clinical Implications of Immune Checkpoints and the RANK/RANK-L Signaling Pathway in High-Grade Canine Mast Cell Tumors
    Noelia C. Talavera Guillén, Andrígo Barboza De Nardi, Felipe Noleto de Paiva, Queila Cristina Dias, Alexandra Pinheiro Fantinatti, Wagner José Fávaro · 2023 · Animals
90. Interferon-α Differentially Affects Homeostasis of Human Plasmacytoid and Myeloid Dendritic Cells
    Vito Rosario Cicinnati, Jinyu Kang, Jing Hou, Monika Lindemann, K Koop, Thomas Tüting, Guido Gerken, Susanne Beckebaum · 2009 · Journal of Interferon & Cytokine Research
91. Historical Perspectives and Current Trends in Cancer Immunotherapy
    Tyler Jay Curiel · 2012 · Springer eBooks
92. A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma
    Yong Cai, Fei Wang, Q. Liu, Z. Li, D. Li, Zhoubing Sun · 2018 · Investigational New Drugs
93. Allogeneic murine pregnancy models for assessing the developmental effects of immune‐stimulating antibodies: Challenges in reproducibility
    Kary E. Thompson, Tracy L. Danberry, Roderick Todd Bunch, Michael J. Graziano, Mary Ellen McNerney · 2019 · Birth Defects Research
94. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody
    Eun Ji Lee, Gun-Young Jang, Sung‐Eun Lee, Ji‐Won Lee, Hee Dong Han, Yeong‐Min Park, Tae Heung Kang · 2021 · Immunology Letters
95. Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer
    Peter S. Goedegebuure · 2011 · Current Cancer Drug Targets
96. Immunologically Privileged Environments
    Mark Peter Hedger · 2007 · Elsevier eBooks
97. Concordance of PD-L1 Expression Detection in Non–Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC)
    Stephen A. Young, Christen Griego-Fullbright, Aaron Wagner, Amanda Chargin, Bruce Kendrick Patterson, Devon Chabot‐Richards · 2018 · American Journal of Clinical Pathology
98. The Many Sounds of T Lymphocyte Silence
    Ignacio Melero, Ainhoa Arina, Lieping Chen · 2005 · Immunologic Research
99. The Current Role of Antiangiogenics in Colorectal Cancer
    Debora Basile, Paola Di Nardo, Maria Grazia Daffinà, Carla Cortese, Jacopo Giuliani, Giuseppe Aprile · 2025 · International Journal of Molecular Sciences
100. Targeted lung Lactobacillus johnsonii intervention alleviates virus-induced fibrosis post-HCT through PD-L1/PD-1 signaling
     Joshua B. Perkins, Keerthikka Ravi, C. Guo, Gina J. Oh, Bellmary G. Rodriguez, Chin-Ning Chen, Selga I. Jansons, Faye Candice S. Sun, Stephen J. Gurczynski, Jason B. Weinberg et al. · 2026 · Science Advances